Topic: Novel Approaches for HCC

Download All Articles

A special issue of Hepatoma Research  (Print ISSN:2394-5079; Online ISSN:2454-2520).

Deadline for manuscript submissions: 30 Jun 2018

Share This Special Issue

Guest Editor(s)

  • Lynn G. Feun, MD
    Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA.

    E-mail

Submission Information:

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at http://www.editorialmanager.com/hres/default.aspx
Submission Deadline: 30 Jun 2018
Contacts: Siqi Li, Assistant Editor, editor001@hrjournal.net

Published Articles Download All Articles
  • Congenital absence of the portal vein complicated by hepatocellular carcinoma in the liver of an adult woman: review of imaging, literature and management

    Ankit Mehta , Shree R. Venkat , Lorraine Portelance , Lynn G. Feun
    We present a case of absence of the portal vein and Laennec’s cirrhosis in a 51-year-old female who was diagnosed with hepatocellular carcinoma (HCC). Only 101 cases of this malformation of the splanchnic vasculature have been reported of which 4 were reported to have HCC. Patient had disease progression while waiting for a liver transplant. Patient was treated with 3 separate conventional... Read more
    This article belongs to the Special Issue Novel Approaches for HCC
    Hepatoma Res 2018;4:7. | doi:10.20517/2394-5079.2017.35
    Published on: 27 Feb 2018  | Viewed:2241  | Downloaded:99
    +HTML| PDF
  • The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings

    Walid S. Ayoub , Francis Dailey , Paul Martin , Patricia D. Jones
    Worldwide, hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality. In men, it is the fifth most common cancer and seventh most common in women; HCC is the second highest cause of cancer-related death worldwide. It is less prevalent in the USA and Northern Europe and more prevalent in Eastern and South-Eastern Asia. Over 700,000 cases are diagnosed each year - half of... Read more
    Hepatoma Res 2017;3:302-8. | doi:10.20517/2394-5079.2016.44
    Published on: 20 Dec 2017  | Viewed:912  | Downloaded:105
    +HTML| PDF
  • Immunotherapy for hepatocellular carcinoma: the force awakens in HCC?

    Lynn G. Feun , Ying-Ying Li , Medhi Wangpaichitr , Chun-Jing Wu , Niramol Savaraj
    Systemic therapy for hepatocellular carcinoma (HCC) has been disappointing. The only drug approved by Food and Drug Administration recently has been sorafenib. Sorafenib has modest benefits with a low response rate and an improvement in time to progression of only 2-3 months. Multiple randomized trials, which compare the new agent to sorafenib as either first line or second line therapy, have... Read more
    Hepatoma Res 2017;3:43-51. | doi:10.20517/2394-5079.2016.45
    Published on: 22 Mar 2017  | Viewed:4650  | Downloaded:957
    +HTML| PDF
Hepatoma Research ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.